Charles D. Smith

TL;DR: Imaging results suggest that intra-brain vascular dysregulation is an early pathological event during disease development, suggesting early memory deficit associated with the primary disease factors.

TL;DR: These compounds are the first examples of nonlipid inhibitors of SK with in vivo antitumor activity and so provide leads for additional development of inhibitors of this important molecular target.

TL;DR: The mechanistic underpinnings by which mutant (V599E)B-RAF promotes melanoma development are identified and the effectiveness of targeting this protein to inhibit melanoma tumor growth is shown.

TL;DR: Results provide the first direct evidence that the fMet-Leu-Phe receptor in PMN membranes is coupled to polyphosphoinositide hydrolysis through an islet-activating protein-sensitive guanine nucleotide regulatory protein.

TL;DR: Oral administration of ABC294640 to mice bearing mammary adenocarcinoma xenografts results in dose-dependent antitumor activity associated with depletion of S1P levels in the tumors and progressive tumor cell apoptosis, and this newly developed SK2 inhibitor provides an orally available drug candidate for the treatment of cancer and other diseases.